Moody's Ratings (Moody's) Moody's Ratings assigned a Ba1 rating to Coty Inc.'s ("Coty") new senior notes due 2031. Coty's subsidiaries HFC Prestige Products, Inc. (HFCPP), and HFC Prestige International U.S. LLC (HFCPI) are co-issuers of the notes. Proceeds are expected to be used to refinance exist...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025A fireside chat at Morgan Stanley’s 23rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, Sept...
Two Directors at Coty Inc bought 290,000 shares at between 3.840USD and 3.916USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $162.1 million cash, cash equivalents and restricted cash as of June 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md....
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On August 4, 2025, the Company issued to these employees options to purchase an aggregate of 5,750 shares of the Company’s common stock with an exercise price of $12.48, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...
Citizens Community Bancorp, Inc. Reports Second Quarter 2025 Earnings of $0.33 Per Share; Board of Directors Authorize 5% Stock Buyback Authorization EAU CLAIRE, Wis., July 28, 2025 (GLOBE NEWSWIRE) -- Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $3.3 million and earnings per diluted share of $0.33 for the second quarter ended June 30, 2025, compared to $3.2 million and earnings per diluted share of $0.32 for the quarter ended March 31, 2025, and $3.7 million and...
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.